Mertiva AB

Equities

MERT A

SE0010023432

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET Other stock markets
- ^SEK	-

2017	Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	CI
2017	Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	CI

Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million.

December 17, 2014 at 11:00 pm EST

Mertiva AB (publ) (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million on December 18, 2014. Mertiva acquired 0.42 million shares in Protein Sciences at a price of $1.5 per share. As a result of transaction, Mertiva now holds 11.8 million shares in Protein Sciences.

Mertiva AB (publ) (OTCPK:DMYD.F) completed the acquisition of an additional 0.54% stake in Protein Sciences Corporation on December 18, 2014.

Latest news about Mertiva AB

Sanofi Pasteur Inc. completed the acquisition of Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others.	17-08-27	CI
Diamyd Medical and Cardiff University to Collaborate on Study Monitoring Immune Response in Lymph Node Cells After Administration of Diamyd	17-08-10	CI
Sanofi Pasteur Inc. agreed to acquire Protein Sciences Corporation from Mertiva AB (NGM:MERT MTF A), Ropart Asset Management Funds, Johnson & Johnson, Pfizer Inc. and others for $750 million	17-07-10	CI
Mertiva AB's Equity Buyback announced on December 6, 2012, has expired.	15-11-28	CI
Mertiva AB (OTCPK:DMYD.F) acquired an additional 0.54% stake in Protein Sciences Corporation for $0.62 million.	14-12-17	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	14-01-21	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	13-10-11	CI
The members of the management of Diamyd, Inc. cancelled the acquisition of 90% stake in Diamyd Inc. from Diamyd Medical AB (OM:DIAM B).	13-10-08	CI
Mertiva AB (OTCPK:DMYD.F) acquired an additional 7.27% stake in Protein Sciences Corporation from Pacific Rim Ventures Co., Ltd. and other shareholders for $8.4 million.	13-09-25	CI
Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic All-Share Index	13-08-27	CI
Mertiva AB(NGM:MERT MTF) dropped from OMX Nordic Small Cap Index	13-07-30	CI
Tranche Update on Mertiva AB (OTCPK:DMYD.F)'s Equity Buyback Plan announced on December 6, 2012.	13-07-04	CI
Diamyd Medical AB Announces Board Appointments	13-04-22	CI
Diamyd Medical AB Names Andreas Bergsten as Chief Executive Officer	13-04-22	CI
Diamyd Medical AB has Changed its Name to Mertiva AB	13-04-22	CI
Mertiva AB Plans to Appoint Andreas Bergsten as President	13-04-19	CI
Diamyd Medical AB Reports Group Earnings Results for the Second Quarter and Six Months Ended February 28, 2013	13-03-27	CI
Tranche Update on Diamyd Medical AB's Equity Buyback Plan announced on December 6, 2012.	13-03-27	CI
Östersjöstiftelsen, Endowment Arm sold 5.1% stake in Diamyd Medical AB (OM:DIAM B).	13-03-06	CI
Diamyd Medical AB Announces New Clinical Study with Diamyd's Diabetes Vaccine	13-01-30	CI
Diamyd Medical AB Announces Group Earnings Results for the First Quarter Ended November 30, 2012	13-01-23	CI
Diamyd Medical AB Announces Board Changes	12-12-06	CI
Diamyd Medical AB's Equity Buyback has expired	12-12-06	CI
Mertiva AB announces an Equity Buyback.	12-12-05	CI
Tranche Update on Diamyd Medical AB's Equity Buyback Plan announced on December 7, 2011.	12-12-05	CI

Chart Mertiva AB

Duration

Period

More charts

Company Profile

Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MERTIVA AB	0.00%	89.46M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research